An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Launched by ARGENX · Jul 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a medication called efgartigimod to see how well different dosing schedules work for patients with Generalized Myasthenia Gravis (gMG), a condition that causes muscle weakness. The trial will compare a continuous treatment regimen to a cyclic one over a period of up to 138 weeks. Participants will have regular visits, including weekly check-ins for the first 21 weeks, to monitor their health and the effectiveness of the treatment.

To join the trial, participants need to be at least 18 years old and have a confirmed diagnosis of gMG, with specific symptoms that affect their daily activities. They must also be willing to sign consent forms and meet certain health criteria, such as not having other serious infections or recent surgeries. This study is actively seeking participants who want to help improve treatments for gMG, and it aims to gather important data about the safety and effectiveness of efgartigimod.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• • At least 18 years of age, at the time of signing the informed consent.
• • Diagnosed with Generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by a physical exam and confirmed seropositivity for anti-acetylcholine receptor antibodies (AChR-Abs).
• • Meets the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, or IV
• • Has an Myasthenia Gravis - Activities of Daily Living (MG-ADL) total score ≥5 at screening and the day 1 visit, with more than 50% of the score due to nonocular symptoms
• • Concomitant gMG treatment is permitted. Permitted concomitant gMG treatment includes nonsteroidal immunosuppressive drugs (NSIDs), steroids, and/or acetylcholinesterase (AChE) inhibitors. If receiving corticosteroids and/or NSIDs, must be on a stable dose for at least 1 month before screening.
• • Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and: Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before investigational medicinal product (IMP) can be administered.
• Exclusion Criteria:
• • Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening
• • A positive test for SARS-CoV-2 at screening
• • Any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of the clinical symptoms of gMG and/or put the participant at undue risk
• • History of malignancy unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time, provided they are adequately treated at screening: Basal cell or squamous cell skin cancer; carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
• • Clinical evidence of other significant serious diseases, a recent (\<3 months) major surgery, or any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk
• • A thymectomy within 3 months of screening
• • Pregnant or lactating females and those who intend to become pregnant during the study or within 90 days of the last dose of IMP
• * Use of the following prior or concomitant therapies:
• • 1. intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) within 14 days of day 1
• • 2. Rituximab within 6 months of day 1
• • 3. Eculizumab within 1 month of day 1
• • 4. Other monoclonal antibodies (eg, adalimumab, tocilizumab, ixekizumab) within 5 half-lives of the monoclonal antibodies before day 1
• • 5. Use of any other investigational product within 3 months or 5 half-lives, whichever is longer, before day 1
• • 6. Receipt of a live or live-attenuated vaccines received within 4 weeks of screening. The receipt of any inactivated, subunit, polysaccharide, conjugate vaccine at any time before screening is not considered exclusionary.
• • Previous participation in a clinical study or patient access program during which they were treated with efgartigimod
• • Positive serum test at screening for an active viral infection with any of the following conditions: Hepatitis B virus (HBV) that is indictive of an acute or chronic infection; Hepatitis C virus (HCV) based on HCV antibody assay (unless associated with a negative HCV RNA test); HIV based on test results that are associated with an AIDS-defining condition or a CD4 count \<200 cells/mm3
• • Total IgG \<6 g/L at screening
• • Known hypersensitivity reaction to efgartigimod or any of its excipients
• • The participant stands in any relationship of dependency with the sponsor.
• • The participant has been institutionalized due to an official or judicial order.